Lannett Company, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Timothy C. Crew
- Full Time Employees
- 564
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1150 Northbrook Drive Trevose PA United States of America 19053
- IPO Date
- Dec 13, 2013
- CIK
- 0000057725
- Website
- lannett.com
- Similar Companies
- Business
- Lannett Company, Inc. (NYSE: LCI) develops, manufactures, packages, markets and distributes generic versions of branded pharmaceutical products primarily in the United States; the company offers solid oral and extended-release dosage forms, topical, liquid, nasal, oral solutions, ophthalmic, patch, foam, buccal, sublingual, suspensions, soft gel, injectable and oral products addressing therapeutic areas including analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary and others; key products encompass Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants and cocaine hydrochloride solution, with expertise in complex generics, DEA-controlled substances, non-opioid ADHD treatments and generic liquids; Lannett operates as a contract development and manufacturing organization with annual capacity for approximately 3.6 billion oral solid doses and 2.0 million liters of liquids across a 425,000 square foot cGMP-compliant facility; the company sells to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities and health maintenance organizations. Founded in 1942 and headquartered in Trevose, Pennsylvania, Lannett maintains manufacturing, research and development, packaging and distribution facilities in Pennsylvania and Indiana. In 2025, Aurobindo Pharma USA, a subsidiary of Aurobindo Pharma Ltd., enters a definitive agreement to acquire Lannett for an enterprise value of $250 million on a cash-free, debt-free basis from Lannett Seller Holdco, strengthening Aurobindo's U.S. manufacturing footprint, product portfolio in ADHD therapeutics and complex generics, and contract manufacturing capabilities; the transaction, subject to regulatory approvals including U.S. Federal Trade Commission clearance, anticipates completion within 8 to 12 months and aligns with reshoring trends given Lannett's excess capacity and trailing twelve-month revenues of $306 million ending March 2025.
LCI Industries Second Quarter 2026 Conference Call Scheduled for August 5, 2026, at 8:30 a.m. ET
LCI Industries Appoints Robert Hureau to Board of Directors
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)
LCI Industries Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LCI Industries - LCII
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)
Patrick Industries and LCI Industries to Combine in All-Stock Merger, Creating a Premier Platform Serving Global Outdoor Enthusiast, Housing and Other Markets
FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett
LCI Industries Announces Leadership Transitions
LCI Industries Declares Quarterly Cash Dividend
LCI Industries Q1 Earnings Call Highlights
LCI Industries Continues To Prove That It Makes For A Good Ride
LCI Industries Reports First Quarter Financial Results
Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA™ an Interchangeable Biosimilar of Lantus® (insulin glargine)
LCI Industries and Patrick Industries Terminate Discussions Regarding Potential Merger of Equals
Patrick Industries and LCI Industries Terminate Discussions Regarding Potential Merger of Equals
LCI Industries Confirms Discussions Regarding Potential Merger of Equals with Patrick Industries, Inc.
Patrick Industries, Inc. Confirms Discussions with LCI Industries Regarding a Potential Merger of Equals
Investor Doubles Down With $8 Million Buy as LCI Industries Hits $4.1 Billion in Sales
LCI Industries Announces Participation in Upcoming Investor Conferences
LCI Industries Declares Quarterly Cash Dividend